Development of a Synthetic Biotic for the Treatment of Phenylketonuria

Time: 2:15 pm
day: Day One – Track B – 2


• Phenylketonuria is a rare inherited disorder of Phenylalanine metabolism, with significant risk of neurocognitive impairment and high unmet need
• Our team at Synlogic has developed SYNB168, an engineered Synthetic Biotic to consume Phe in the GI tract that demonstrated fasting plasma Phe lowering in patients with PKU
• The SYNB1618 clinical data validate Synlogic’s mathematical modeling approach for the development of Synthetic Biotic medicines